. Author manuscript; available in PMC: 2013 Oct 28.

Published in final edited form as: J Am Soc Echocardiogr. 2009 Jun 23;22(8):10.1016/j.echo.2009.05.002. doi: 10.1016/j.echo.2009.05.002

Table 3.

Prevalence of FDA grade regurgitation with anorectic drug use.

Study Author (ref #)	Medication	Number of patients	Treatment duration (mean)	FDA-grade AR Prevalence		FDA-grade MR Prevalence

				Cases	Controls	Cases	Controls
Weissman, ref #24	Dexfenfluramine	342	72 Days	5.0%	3.6%	1.7%	1.2%
	Dexfenfluramine	329	71 Days	5.8%	3.6%	1.8%	1.2%
	Combined Dex. groups	671	72 Days	5.4%	3.6%	1.8%	1.2%
Burger, ref #27	Fenfluramine-phentermine	226	13 months	6.6%	4.9%^**	1.3%	1.6%^**
Shivley, ref # 26	Dexfenfluramine	223	7 months	6.3% ^*	1.6%	1.3%	0.5%
Gardin, ref #28	Dexfenfluramine	479	6 months	8.9% ^*	4.1%	4.9%	3.2%
Gardin, ref #28	Fenfluramine-phentermine	455	12 months	13.7% ^*	4.1%	5.1%	3.2%

AR, aortic regurgitation; MR, mitral regurgitation.

Statistically significant prevalence (vs normal controls).

^**

Framingham Heart Study Prevalence (controls not used in this study)